Niemann-Pick disease Type C is a rare genetic disorder characterized by the deficiency of lysosomal cholesterol transport. The accumulation of excessive cholesterol and other fatty substances causes damage to liver and neurodegenerative problems. The current treatment landscape remains limited with only one approved therapy. The growing research and development activities focused on developing new drug molecules offer a ray of hope to patients. Several candidate drugs are in Phase I, Phase II and Phase III stages of clinical trials evaluating their safety and efficacy in Type C patients.
The global Niemann-Pick disease Drug Type C Treatment Market is estimated to be valued at US$ 55.39 Mn in 2023 and is expected to exhibit a CAGR of 22% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The robust pipeline with over 15 drug candidates in different stages of development presents a significant growth opportunity. Many of these pipeline drugs have demonstrated encouraging pre-clinical results and have the potential to receive regulatory approvals in the coming years. This will meet the currently unmet need and expand treatment options for Niemann-Pick disease Type C patients. Additionally, favorable orphan drug designations and priority review vouchers given by regulatory bodies are expected to accelerate their commercialization, benefitting patients as well as market players.
Porter's Analysis
Threat of new entrants: The threat of new entrants is low due to high capital requirements for R&D and manufacturing along with patents protecting existing therapies.
Bargaining power of buyers: The bargaining power of buyers is moderate as the disease is rare and patients have limited treatment options.
Bargaining power of suppliers: The bargaining power of suppliers is moderate as there are a few manufacturing players and drug developers.
Threat of new substitutes: The threat of new substitutes is high as research for new therapies is ongoing which can replace existing treatments.
Competitive rivalry: The competitive rivalry is high among key players to develop and commercialize successful therapies.
SWOT Analysis
Strength: Existing drugs provide treatment options and increase awareness about the disease. Higher healthcare spending supports R&D for new therapies.
Weakness: Rare disease status poses commercialization challenges. High development costs and regulatory hurdles.
Opportunity: Large patient pool in developing countries remains untapped. Collaborations can help accelerate drug development.
Threats: Failure of pipeline drugs in clinical trials. Patent expiry of major drugs results in revenue loss.
Key Takeaways
The Global Niemann-Pick Disease Drug Type C Treatment Market Size is expected to witness high growth over the forecast period. The global Niemann-Pick disease Drug Type C Treatment Market is estimated to be valued at US$ 55.39 Mn in 2023 and is expected to exhibit a CAGR of 22% over the forecast period 2023 to 2030.
Regional analysis related content: North America is expected to hold largest market share during forecast period majorly driven by presence of key players and increasing research activity on rare diseases treatment in the US. Europe is also anticipated to grow at significant rate during forecast period owing to increasing government funding for rare disease research in countries like France and Germany.
Key players related content: Key players operating in the Niemann-Pick Disease Drug Type C Treatment market are Johnson & Johnson, Intrabio, Cyclo Therapeutics, Inc., Kempharm, Inc., Azafaros B.V., StrideBio. Sarepta Therapeutics, Inc. Johnson & Johnson has strong product portfolio and geographical presence which provides it an edge over other players.
Get More Insights On This Topic: https://www.newsanalyticspro.com/the-global-niemann-pick-disease-drug-type-c-treatment-market-is-propelled-by-increasing-disease-diagnosis/
Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reportsThe Orphan Drugs Global Market Report 2020-30 by The Business Research Company describes and explains the global orphan drugs market and covers 2015 to 2020, termed the historic period, and 2020 to 2025, termed the forecast period, along with further forecasts for the period 2025-2030.
The report evaluates the market across each region and for the major economies within each region.The Orphan Drugs Global Market Report 2021 covers orphan drugs market drivers, orphan drugs market trends, orphan drugs market segments, orphan drugs market growth rate, orphan drugs market major players, and orphan drugs market size.
View Complete Report:https://www.thebusinessresearchcompany.com/report/orphan-drugs-market-global-report The orphan drugs market report provides an in-depth analysis of the impact of COVID-19 on the global orphan drugs industry, along with revised market numbers due to the effects of the coronavirus and the expected orphan drugs market growth numbers 2021-2030.Orphan Drugs Global Market Report 2021 is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies.
The chapter on the impact of COVID-19 gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market.
The chapter also covers markets which have been positively affected by the pandemic.Request For The Sample Now: https://www.thebusinessresearchcompany.com/sample.aspx?id=2823=smp The global orphan drugs market is expected to grow from $135.2 billion in 2020 to $141.91 billion in 2021 at a compound annual growth rate (CAGR) of 5%.
The orphan drugs market is expected to reach $183.27 billion in 2025 at a CAGR of 7%.The report covers the orphan drug market segments- 1) By Therapy Area: Oncology, Blood, Central Nervous System, Endocrine, Cardiovascular, Respiratory, Immunomodulatory.2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Sales.3) By Drug Type: Biological, Non-Biological.4) By Disease Type: Oncology, Hematology, Neurology, Cardiovascular, Others.About The Business Research Company: The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research.
The Alzheimer’s Disease Drug market research report provides the latest industry data, growth, key segments and future trends on the basis of the detailed study.
This market report also allows you to identify the future opportunity and growth rate of the leading segment based on regions and countries.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the alzheimer’s disease drug market include Allergan, Eisai, Novartis, Daiichi Sankyo,Pfizer, Johnson and Johnson, Lundbeck.S.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Alzheimer’s Disease Drug Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/alzheimers-disease-drug-market/download-sampleMarket DynamicsThe increase in the prevalence of Alzheimer's disease and the aging population is the primary factor driving the alzheimer's disease drug market.
According to the WHO, there are around 50 million Alzheimer's disease cases globally.
The growing demand for personalized drugs and affordable diagnostics tests contributes to the growth of the alzheimer's disease drug market.
